[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 8, 2011

Bevacizumab and Cancer Treatment-Related Mortality—Reply

Author Affiliations

Author Affiliations: Division of Hematology and Medical Oncology, Stony Brook University School of Medicine, Stony Brook, New York (shenhong.wu@stonybrook.edu).

JAMA. 2011;305(22):2291-2293. doi:10.1001/jama.2011.760

In Reply: Dr Yang and colleagues identified a number of errors in our study related to incorrect data extraction. They are right, and a correction appears in this issue. We regret the errors. Overall, the final results and conclusions did not change substantially.

The goal of our study was to provide insight into the risk of FAEs related to chemotherapy associated with a biological agent, in this case bevacizumab. These events are most likely the result of serious adverse effects from the treatment, as shown in our study. We agree with Dr Punt and colleagues that many FAEs could be prevented by better adherence to treatment guidelines and adequate patient care. However, our study, being a meta-analysis, was limited in assessing these issues. The included studies did not contain any information regarding the assessment of the relationship between FAEs and treatment and major protocol violations and monitoring results.

First Page Preview View Large
First page PDF preview
First page PDF preview
×